Visit Counter :
Customer Services
Sealand Enterprises Ltd.
Rm 301-303, 3/F, Tai Yip Building,
141 Thomson Road, Wanchai, Hong Kong

Tel (852) 2512 1086
Fax (852) 2512 1609


Office hours :
Mon- Fri
09:00 -18:00
Sunday and Public
Holidays: Closed

Coriolus Versicolor PSP
Coriolus Versicolor PSP
  • Coriolus Versicolor PSP was invented by a Shanghai Normal University expert team led by Professor Q.Y. Yang in 1982, and the corresponding patent was granted to Shanghai Normal University in 1989. With the approval of the Ministry of Health, and later the State Food and Drugs Administration Bureau, Shanghai Xinkang Pharmaceutical Factory has been the authorized sole manufacturer of the patented Coriolus Versicolor PSP.
  • PSP stands for Polysaccharide Peptide, a protein-bound polysaccharide extracted from deep-layer-cultivated mycelia of the COV-1 strain of Coriolus Versicolor, commonly known as Yunzhi.
Coriolus Versicolor PSP
  • Coriolus Versicolor Polysaccharopeptide (PSP) is indicated for adjunct treatment with radiotherapy and chemotherapy. It alleviates leucopenia and depressed body immunity caused by radiotherapy and chemotherapy, as well as alleviates other symptoms of malaise, such as anorexia, nausea and vomiting, mouth ulcers, insomnia, spontaneous perspiration and night sweating. It reduced the feeling of pain and improve appetite. Since it does not cause any undesirable side effect, it can be used for people feeling weak and having depressed body immune function for prolonged period. It is also used for prevention of disease, particularly for those who have a family history of serious illnesses such as cancer. It is generally used by people who have recovered after treatment of radiotherapy and chemotherapy for preventing recurrence of illnesses.
  • Improves appetite, sleeping quality, and patients’ overall quality of life
  • A product that has gone through stringent clinical trials, and it has been extensively researched and wrote about by researchers, pharmacologists, oncologists of the Chinese mainland, Hong Kong University, Hong Kong Chinese University, Hong Kong Polytechnic University, the US, UK, Korea, Japan, etc. Two international conferences were specially convened on PSP in 1993, 1989 & 1999 in Hong Kong
  • It is a pure natural extract of Coriolus Versicolor (commonly known as Yunzhi). Since it was available in the market 20 years ago, over a million patients have used PSP and benefited from it – a sound record of proven efficacy and free of any side effect. It is the most mature product of its kind in the market.
PSP History
  • 70s
    Japanese scientists were the first who did research on Coriolus Versicolor employing modern technology, and successfully extracted a polysaccharide (PSK) from the COV-101 strain. PSK is patented and proven that it can effectively enhance immunity of human body.
  • Early 80s
    An expert team led by Prof. Q.Y. Yang of Shanghai Normal University conducted extensive research on nearly 100 strains of Coriolus versicolor, identified and extracted a polysaccharide petide (PSP) from the deep cultivated mycelium of COV-1 strain. Scientific tests showed that the effectiveness of PSP was even better than PSK, which was then a popular medicine in Japan for treatment of cancer patients. When news hit the street, PSP immediately gained interntional attention.
  • 1987-89
    The patent on PSP was granted to the Shanghai Normal University. (Patent No: 89105471)
  • 1989
    The first “PSP” international conference was convened in Hong Kong.
  • 1991-92
    Stage I, II and III double-blind randomized placebo-controlled clinical trials were conducted through 24 specialist hospitals with more than 1,100 cancer patients in major cities in China. The clinical trials and the subsequent registration of “Coriolus versicolor PSP” as a new medicine was approved by Ministry of Health in China. In the same year, Shanghai Normal University established Shanghai XinKang Pharmaceutical Factory, with which exclusively used the patent right and manufactured the medicine “Coriolus versicolor PSP”.
  • 1992
    “Coriolus versicolor PSP” has been extensively researched and written about by experts and researchers of the University of Hong Kong, Chinese University of Hong Kong , Polytechnic University of Hong Kong, major universities on mainland China, Taiwan, the US, UK, Japan, S. Korea, New Zealand, and Taiwan. The US National Library of Medicine has collected about 200 “Coriolus versicolor PSP” related clinical reports and research papers.
  • 1993
    The second “Coriolus versicolor PSP” international conference was convened in Hong Kong.
  • 1999
    The third “Coriolus Versicolor PSP” international conference, titled “Advanced Research in PSP” was convened in Hong Kong. In the same year, a double-blind randomized placebo-controlled clinical trial was conducted by University of Hong Kong in Queen Mary Hospital. The clinical trial confirmed again its efficacy to complement radiotherapy and chemotherapy treatments.
  • 2006
    Shanghai Xinkang Pharmaceutical Factory acquired Hong Kong Sealand Enterprises Ltd. and officially appointed Sealand as the sole distributor of “Coriolus Versicolor PSP” for the Hong Kong, Macau and oversea markets, under the brand name of “Qing Kang ®”.
  • 2008
    Qing Kang ® PSP was granted the transitional registration number of Chinese Proprietary Medicine from the Chinese Medicine Council of Hong Kong. Registration number: HKP-07947.
  • 2011
    Qing Kang ® PSP was among the first few Chinese Proprietary Medicine which had fully satisfied the requirements of the Chinese Medicine Council of Hong Kong, passed through the transitional registration and was granted the full registration number: HKC-16425. In the same year, Qing Kang ® PSP also got Thailand Government’s FDA approval (lot number: K15/54), and Sealand started the product’s official launch in the country through its local distributor.
  • 2012
    Qing Kang ® PSP got the approval from Health Canada (Product Licence/ NPN: 80032867) to make the product officially available to users in Canada.